Eledon reports Q1 net loss $10.8M; clinical and financing updates on tegoprubart

Eledon Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.75

Net loss of $10.8M ($0.75/share) vs $9.9M ($0.69) in Q1 2022; R&D expenses rose to $8.1M.
Cash $46.5M at March 31; second-quarter financing provided $35M upfront (up to $185M) to fund Phase 2 BESTOW.
Phase 1b kidney transplant data (3 patients): no acute rejection; mean eGFR >70 mL/min/1.73m2 at timepoints up to 31 weeks.
Phase 2a IgAN study: tegoprubart safe and well tolerated; no serious/severe AEs; 4 patients completed ≥24 weeks.
Phase 2 BESTOW trial expected to initiate mid-2023; updated Phase 1b data anticipated late 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eledon Pharmaceuticals, Inc. reported three months ended March 31, 2023 results: net income net loss of $10.8 million, or $0.75 per share, EPS $0.75 per share.

Period: three months ended March 31, 2023
Net income: net loss of $10.8 million, or $0.75 per share
EPS: $0.75 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $10.8 million, or $0.75 per share, for the three months ended March 31, 2023, compared to a net loss of $9.9 million, or $0.69 per share, for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021198

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.